| Form | Liquid |
|---|
| Host Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1-kappa |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1.82mg/ml |
|---|
| Endotoxin Level | Please contact the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | 5, 6-dihydroxyindole-2-carboxylic acid oxidase, Glycoprotein 75, CAS2, TYRP1, TRP-1, TYRRP, TRP1, Catalase B, TYRP, Melanoma antigen gp75, TRP, DHICA oxidase, Tyrosinase-related protein 1 |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | P17643 |
|---|
| Background | Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance.
|
|---|
| Alternative Names | 20D7S, IMC-20D7S, 1188277-05-5 |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|